BiotechTube
Oakwood Labs

Oakwood Labs

Cleveland, United States· Est.
oakwoodlabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.5M

Overview

Oakwood Labs is a private, established player in the drug delivery sector, focusing on its proprietary Microsphere technology platform. The company operates as a contract development and manufacturing organization (CDMO), providing formulation, process development, and GMP manufacturing services to partners advancing long-acting injectable (LAI) products. Its business model is centered on collaborative partnerships, leveraging its deep expertise in complex injectable formulations to support clients from pre-clinical stages through commercialization. While not developing its own therapeutics, Oakwood's technology enables improved patient compliance and enhanced therapeutic profiles for a wide range of drugs.

Drug Delivery

Technology Platform

Proprietary Microsphere technology for sustained-release injectable formulations, utilizing biodegradable polymers (e.g., PLGA) to encapsulate drugs for controlled release over weeks to months.

Funding History

2
Total raised:$7.5M
Grant$2.5M
Seed$5M

Opportunities

The growing demand for long-acting injectables to improve patient compliance in chronic diseases presents a major opportunity.
Expansion into formulating complex molecules like peptides, proteins, and potentially new modality drugs (e.g., for gene therapy) could open new market segments.

Risk Factors

High dependence on the success of partner clinical programs creates client concentration and pipeline risk.
Competition from larger CDMOs and alternative drug delivery technologies threatens market share.
The capital-intensive nature of GMP manufacturing pressures financial performance.

Competitive Landscape

Oakwood competes with other specialized drug delivery CDMOs (e.g., Pacira BioSciences' former CDMO business, Evonik's Resomer polymers division) and large, full-service CDMOs (Lonza, Catalent) that have complex injectables capabilities. Its differentiation lies in its deep, focused expertise specifically in microsphere-based sustained release.

More companies in Drug Delivery & Formulation →More companies in United States →